Edgewise Therapeutics (EWTX) Revenue & Revenue Breakdown
Edgewise Therapeutics Revenue Highlights
00
Edgewise Therapeutics Revenue by Period
Edgewise Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | - |
Edgewise Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $2.25M | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | - |
Edgewise Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
HOWL | Werewolf Therapeutics | $19.94M | $1.14M |
RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
IKNA | Ikena Oncology | $9.16M | - |
IPSC | Century Therapeutics | $2.23M | $791.00K |
BCEL | Atreca | $770.00K | $80.00K |
DSGN | Design Therapeutics | - | - |
CGEM | Cullinan Oncology | - | - |
BDTX | Black Diamond Therapeutics | - | - |
CCCC | C4 Therapeutics | - | - |
DBTX | Decibel Therapeutics | - | - |
TALS | Tourmaline Bio | - | - |
ACET | Adicet Bio | - | - |
PASG | Passage Bio | - | - |
ELYM | Eliem Therapeutics | - | - |
CELC | Celcuity | - | - |
MLYS | Mineralys Therapeutics | - | - |
VOR | Vor Biopharma | - | - |
EWTX | Edgewise Therapeutics | - | - |
XLO | Xilio Therapeutics | - | $2.36M |